arrow
P

Priyanka Sharma

University of Kansas Medical Center
H指数:49
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy

在美国接受内分泌治疗后激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌患者的治疗模式及结局的回顾性观察队列研究

2026-09-220
OAAI
AI-driven resolution of uncertain histopathology in cases initially misdiagnosed as triple-negative breast cancer

人工智能驱动下对最初被误诊为三阴性乳腺癌病例的不确定性组织病理学的解析

2026-08-310
OAAI
Recurrence Score gene group components and outcomes in the RxPONDER trial (SWOG S1007)

复发评分基因组成分与RxPONDER试验(SWOG S1007)中的结果

2026-07-150
PRE
Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America

美国激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌患者接受瑞博西尼联合芳香化酶抑制剂或芳香化酶抑制剂单药一线治疗后的真实世界进展后结局

2026-07-010
OAAI
Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer

398,238名女性的全基因组关联研究揭示了七个与高级别浆液性卵巢癌相关的位点

2025-11-200
OAAI
Analysis of the Radiosensitivity Index (RSI) in Paired Pre- and Post-Neoadjuvant Therapy Triple-Negative Breast Cancer

配对新辅助治疗前后的三阴性乳腺癌中放射敏感性指数(RSI)的分析

2025-09-250
PRE
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data

MammaPrint预测HR+HER2-早期乳腺癌的化疗获益:FLEX登记研究真实世界数据

2025-08-110
OAAI
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer☆

循环肿瘤DNA突变景观和进展后使用CDK4/6抑制剂的动态变化:PACE II期临床试验中转移性HR阳性/HER2阴性乳腺癌☆

2025-07-250
OAAI
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

基质肿瘤浸润淋巴细胞和TNBC-DX在 triple-negative breast cancer 中提供互补的预后信息

2025-07-011
PRE
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
2025-02-130
OA
Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
2024-05-020
PRE
SMARCA2 compensation of SMARCA4 loss mediates adaptive resistance to neoadjuvant systemic therapy in triple-negative breast cancer: paired transcriptomic analysis of pre- and post-treatment samples from NeoSTOP and NeoPACT
2024-05-020
PRE
Tumor infiltrating lymphocyte stratification refines AJCC TNM staging based outcomes of early-stage triple negative breast cancer treated with neoadjuvant anthracycline-free, docetaxel and carboplatin chemotherapy
2024-05-020
PRE